A9 region in EPHB2 mutation is frequent in tumors with microsatellite instability. Analysis of prognosis.
OBJECTIVE
The aim of the present study was to determine the relation of EPH tyrosine kinase receptor B2 (EPHB2) A9 region mutation and microsatellite instability (MSI); and to analyze their influence in prognosis of patients with sporadic colorectal cancer (CRC).


METHODS
A total of 481 patients with CRC were examined. MSI (NCI criteria) and EPHB2 were analyzed using PCR and fragment analysis software.


RESULTS
EPHB2 mutation was detected in 3.1% of patients. Mutation of EPHB2 was associated with location and with MSI status. We considered low instability (L-MSI) when only one marker showed instability, high instability (H-MSI) when two or more markers were positive and microsatelllite stable (MSS) when no instability was detected. The stratified analysis of overall survival (OS) and disease-free survival (DFS) in MSI according to EPHB2 status revealed no statistically significant differences. However, the risk of recurrence of H-MSI tumors with EPHB2 mutation carriers was 3.6-times higher than in non-mutation carriers.


CONCLUSIONS
The frequency of EPHB2 mutation is higher in patients with H-MSI than MSS tumors. Promising results were found regarding the prognostic influence of EPHB2 in H-MSI.
Department of Genomics, Hospital Clínico San Carlos. c/Martín Lagos s/n, 28040 Madrid, Spain. sara.rafael.f@gmail.com.
Sara
S
Rafael
Marta
M
Vidaurreta
Silvia
S
Veganzones
Virgnia
V
De La Orden
Beatriz
B
Mediero
Maria Luisa
ML
Gutierrez
Maria Luisa
ML
Maestro
D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D002288:Adenocarcinoma, Mucinous / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D053842:Microsatellite Instability; D009154:Mutation / Q000235:genetics*; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D036183:Receptor, EphB2 / Q000235:genetics*; D015996:Survival Rate
D014408:Biomarkers, Tumor; D036183:Receptor, EphB2
Disease-free survival; kinase receptor family; molecular markers; sporadic cancer; tumor suppressor